Lupin receives USFDA tentative approval for Doxycycline Capsules

9 Nov 2022 , 09:16 AM

Global pharma major Lupin Limited has announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Doxycycline Capsules, 40 mg.

As per the filing, the received USFDA approval is to market a generic equivalent of Oracea Capsules, 40 mg, of Galderma Laboratories, L.P.

According to the IQVIA MAT September 2022 data, Doxycycline Capsules (RLD Oracea) had estimated annual sales of USD 215 million in the US.

On Wednesday early morning trade, Lupin Ltd is currently trading at Rs712 per share up by Rs2.2 or 0.31% from its previous closing of Rs709.80 per share on the BSE.

For feedback and suggestions, write to us at [e-mail]